Ardelyx, Inc. revenue
Ardelyx, Inc.'s revenue was $407m in fiscal 2025, up 22.1% on the year before. Since fiscal 2012 ($5.4m) it has grown at a compound 43.3% a year. Over the last twelve months it was $451m.
Revenue history
| Fiscal year | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5 | 29 | 32 | 24 | 42 | 3 | 5 | 8 | 10 | 52 | 124 | 334 | 407 | 451 |
| Growth on the year before | — | +434.7% | +9.3% | −24.0% | +74.8% | −93.8% | +102.6% | +43.4% | +33.4% | +416.6% | +138.6% | +168.1% | +22.1% | — |
| Gross profit | — | — | — | 24 | 34 | 2 | 5 | 7 | 9 | 48 | 107 | 283 | 368 | 425 |
| Gross margin | — | — | — | 100.0% | 80.0% | 82.1% | 88.6% | 98.1% | 90.1% | 92.1% | 85.7% | 84.8% | 90.3% | 94.4% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Products | $378M | 92.8% | ▲ 18.4% |
| Product IBSRELA (part of Products) | $274M | 72.6% | ▲ 73.2% |
| Product XPHOZAH (part of Products) | $104M | 27.4% | ▼ 35.6% |
| Product Supply Revenue | $15.9M | 3.9% | ▲ 36.3% |
| Non Cash Royalty Related To Sale of Future Royalties | $8.5M | 2.1% | ▲ 217.4% |
| Licenses | $5.1M | 1.2% | ▲ 6423.1% |
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $378M | 92.8% | ▲ 18.4% |
| Asia Pacific | $29.2M | 7.2% | ▲ 103.4% |
| North America | $342,000 | 0.1% | ▲ 338.5% |
From Ardelyx, Inc.'s 10-K filed February 19, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Ardelyx, Inc. | $451m | 16.8% | 75.9% |
| Cormedix Inc. | $462m | 280.5% | 1135.4% |
| Arcutis Biotherapeutics, Inc. | $464m | 76.1% | 241.4% |
| Krystal Biotech, Inc. | $470m | 26.0% | 280.1% |
| Novavax Inc | $414m | -61.6% | -36.3% |
| Meiragtx Holdings plc | $398m | 948.3% | 296.0% |
Compare with peers
- Cormedix Inc. revenue
- Arcutis Biotherapeutics, Inc. revenue
- Krystal Biotech, Inc. revenue
- Novavax Inc revenue
- Meiragtx Holdings plc revenue
Head to head: ARDX vs CRMDARDX vs ARQTARDX vs KRYS
More: Biotechnology stocks compared, Health Care sector, rankings of US companies